US2008176964A1PendingUtilityA1

Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies

Assignee: ALCON RES LTDPriority: Apr 30, 2002Filed: Feb 1, 2008Published: Jul 24, 2008

Est. expiryApr 30, 2022(expired)· nominal 20-yr term from priority

Inventors:Debra L. Fleenor Allan R. Shepard Nasreen Jacobson Iok-Hou Pang Abbot F. Clark

A61P 43/00A61P 9/12A61P 27/06A61K 31/427A61K 31/52A61P 27/02A61K 31/519A61K 31/426A61K 31/202A61K 31/4439A61K 38/18A61K 48/00A61K 38/43C12N 9/99

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention provides a method for lowering intraocular pressure and providing neuroprotection to a patient in need thereof by administering a therapeutically effective amount of at least one non-nucleotide or non-protein agent that inhibits expression and/or signaling of connective tissue growth factor (CTGF).

Claims

exact text as granted — not AI-modified

1 . A composition for lowering intraocular pressure and providing neuroprotection in a patient in need thereof, said composition comprising at least one agent that inhibits the expression, signaling, or biological functions of connective tissue growth factor (CTGF) and a pharmaceutically acceptable carrier. 
     
     
         2 . A composition according to  claim 1 , wherein the total concentration of said CTGF inhibitor in said composition is from 0.01% to 2%. 
     
     
         3 . A composition according to  claim 1 , wherein said CTGF inhibitor is a CDK inhibitor.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.